4. Conclusions
In summary these results strongly support the idea that AAPs and DPIV represent a promising target complex for the pharmacological therapy of T cell-mediated diseases by preserving and enhancing endogenous immunosuppressive mechanisms. Whereas inhibitors of AAPs appear to preferentially act on CD4+CD25+ regulatory T cells by preserving their immunosuppressive activity via enhanced expression of immunosuppressive cytokines and FOXP3, inhibition of DPIV leads to increased production/release of TGF-β1 and inhibition of cellular proliferation of predominantly activated effector T cells. Thus, specific inhibition of DPIV and AAPs via small molecular compounds provides a new approach for the pharmacological treatment of autoimmune and inflammatory diseases that simultaneously interferes with two major axis of T cell function.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ansorge S, Reinhold D, Lendeckel U, 2003, Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch. 58: 580–589.
Baecher-Allan C, Brown JA, Freeman GJ, and Hafler DA, 2003, CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp. 252: 67–88; discussion 88–91, 106–114.
Bukowska A, Tadje J, Arndt M, Wolke C, Kähne T, Bartsch J, Faust J, Neubert K, Hashimoto Y, and Lendeckel U, 2003, Transcriptional regulation of cytosol and membrane alanyl-aminopeptidase in human T cell subsets. Biol Chem. 384: 657–665.
Hori S, Nomura T, and Sakaguchi S, 2003, Control of regulatory T cell development by the transcription factor Foxp3. Science. 299: 1057–1061.
Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S, 1999, Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 162: 5317–5326.
Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D, 1999, Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med. 4: 3–15.
Khattri R, Cox T, Yasayko SA, and Ramsdell F, 2003, An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 4: 337–342.
Lendeckel U, Bukowska A, Lättig JH, and Brandt W, 2004, Alanyl-aminopeptidases in human T cells. Structures and functions. In Aminopeptidases. N.M. Hooper and U. Lendeckel, editors. Kluwer Academic/Plenum Publishers, New York, Boston, Dordrecht, London, Moscow.
Lendeckel U, Arndt M, Frank K, Wex T, and Ansorge S, 1999, Role of alanyl aminopeptidase in growth and function of human T cells (review). Int J Mol Med. 4: 17–27.
Lendeckel U, Arndt M, Bukowska A, Tadje J, Wolke C, Kähne T, Neubert K, Faust J, Ittenson A, Ansorge S, and Reinhold D, 2003, Synergistic action of DPIV and APN in the regulation of T cell function. Adv Exp Med Biol. 524: 123–131.
O’Garra A and Vieira P, 2004, Regulatory T cells and mechanisms of immune system control. Nat Med. 10: 801–805.
Sakaguchi S, 2003, The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest. 112: 1310–1312.
Thornton AM and Shevach EM, 1998, CD4+4CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 188: 287–296.
Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, and Ziegler SF, 2003, Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25− T cells. J Clin Invest. 112: 1437–1443.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Bank, U. et al. (2006). Dipeptidylpeptidase IV (DPIV) and Alanyl-Aminopeptidases (AAPs) as a New Target Complex for Treatment of Autoimmune and Inflammatory Diseases—Proof of Concept in a Mouse Model of Colitis. In: Lendeckel, U., Reinhold, D., Bank, U. (eds) Dipeptidyl Aminopeptidases. Advances in Experimental Medicine and Biology, vol 575. Springer, Boston, MA . https://doi.org/10.1007/0-387-32824-6_15
Download citation
DOI: https://doi.org/10.1007/0-387-32824-6_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-29058-4
Online ISBN: 978-0-387-32824-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)